To establish models for studying recurrence of visceral leishmaniasis, a growing problem in T cell-deficient patients, two approaches were investigated: treatment of euthymic BALB/c mice with quiescent Leishmania donovani infection with T cell-depleting or anti-cytokine antibodies and serial observation of acutely infected nude BALB/c mice after an initial antileishmanial response induced by amphotericin B treatment. In chronically infected euthymic mice, maintenance of acquired immunity and prevention of relapse required CD4 cells and a multicytokine-dependent mechanism involving endogenous interleukin-2, interferon-'}', and tumor necrosis factor-a. Acutely infected nude mice responded to amphotericin B with a ?;85% reduction in liver parasite burdens; however, after a brief lag, visceral infection readily recurred in the posttreatment period. Both models may be useful for testing experimental interventions designed to reduce relapse of previously controlled visceral leishmaniasis in T cell-deficient hosts.
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Despite being rendered clinically quiescent by drug therapy or a spontaneous immune response [1, 2] , visceral leishmaniasis (kala-azar) is nevertheless prone to relapse. Increasing parasite drug resistance or suboptimal treatment regimens (or· both) likely contribute to relapse in otherwise healthy persons [3] . In areas in which the disease is endemic, however, recrudescence is also now recognized as a growing clinical problem in 2 T cell-impaired populations: CD4 cell-deficient patients with advanced human immunodeficiency virus (HIV) infection [4] and patients treated with immunosuppressive agents [5] . Relapse in such persons is not surprising because successful host defense in visceral leishmaniasis is T cell-dependent [6', 7] and because visceral parasites are probably seldomly eliminated entirely by either drug treatment or the immunologic mechanisms of spontaneously acquired resistance [7] .
To experimentally investigate relapse ofkala-azar in T celldeficient hosts, we have developed two models in Leishmania donovani-infected animals. One model uses chronically infected euthymic mice subjected to depletion of T cells or relevant cytokines and the other uses T cell-deficient nude mice that have responded to prior chemotherapy. Both models should be helpful in future testing of experim~ntal interventions designed to reduce relapse of kala-azar in T cell-impaired patients.
Materials and Methods
Visceral infection. Female euthymic BALB/c mice (Charles River Breeding Laboratories, Wilmington, MA) and athymic (nude) BALB/c mice (Life Sciences, St. Petersburg, FL) weighing 20-30 g were infected via the tail vein with 1.5 X 10 7 1. donovani amastigotes as described [8] . At the indicated time points, visceral infection was assessed in liver imprints by microscopic counting; liver parasite burdens are expressed as Leishman-Donovan units (LDU) [8] . Data analysis was done using Kruskal-Wallis one-way analysis on ranks; Dunn's method was used for multiple comparisons [9] .
Treatment of euthymic mice with T cell-depleting or anticytokine antibodies. Euthymic mice, which reduce visceral burdens by 80%-90% within 8 weeks [8] , were left undisturbed for 6 months after infection. After that length of time and for 6-12 additional months, euthymic mice remain healthy, show low levels of persistent visceral infection « 100 LDU), and, as judged by resistance to rechallenge, remain solidly immune to 1. donovani [8] .
Six months after infection, immune mice were sacrificed to determine baseline liver burdens. Groups of 3 to. 4 mice were injected intraperitoneally (ip) for 8 weeks using previously described antibody preparations and administration schedules [6, [8] [9] [10] (see legend to figure 1) that inhibit acquired resistance in naive mice [6, 9, 10] and resistance to rechallenge in immune mice [8] . The preparations included 1 mL of hybridoma culture supernatants containing rat anti-mouse monoclonal antibodies (MAbs) GK 1.5 (anti-CD4, ATCC TIB 207, 8 j-tg/mL IgG), 53-6.72 (anti-CD8, ATCC TIB 105, 12 j-tg/mL IgG), and S4B6.1 (anti-interleukin [IL]-2, 12.5 j-tg/mL IgG) or 25 j-tg of normal rat IgG (Sigma, St. Louis) suspended in saline. They also included 0.2 mL of normal rabbit serum, rabbit anti-mouse tumor necrosis factor-a (TNF-a) antiserum (1.5 X 10 5 neutralizing U/mL), or rabbit anti-mouse interferon-y (IFN-y) antiserum (l05 neutralizing U/mL) [6, [8] [9] [10] . Fluorescence analysis of spleen cells [6] from mice treated with anti-CD4 or anti-CD8 revealed 89%-92% depletion of the targeted T cell subset at the end of the first week of injections; comparable depletion (>90%) was maintained at week 8 by twiceweekly MAb injections (data not shown).
Treatment ofnude mice with amphotericin B. Two weeks after infection, liver parasite burdens were determined, and groups of 3 nude mice were treated ip with 5 mg/kg/day of amphotericin B (Fungizone; E. R. Squibb & Sons, Princeton, NJ) every second JID 1996; 173 (April) Discussion Figure 2 . Recurrence of visceral leishmaniasis in nude BALB/e mice following treatment. Starting 2 weeks after infection (day 0), euthymic (0) and nude mice (e) received injections of amphotericin B on days 1, 3, and 5 (bar). Liver burdens were determined on day 7 and 3 and 12 weeks after treatment was completed. Results· are mean ± SE for 6 mice at each time point (2 experiments). * P < .05 compared with day 7 result. LDU, Leishman-Donovan units. 
> :.::J after treatment in a T cell-deficient host. While these mice do not respond to conventional antimony unless reconstituted with T cells [11, 12] , they do respond normally to amphotericin B [11] , a potent leishmanicidal agent with increasing clinical use [13, 14] , To test the hypothesis that posttreatment relapse would likely develop in the absence of T cells, infected nude mice were first treated with amphotericin B for 1 week and then left undisturbed for up to 12 additional weeks. As shown in figure  2 , liver parasite burdens in euthymic mice continued to decline after treatment; the opposite result was observed in nude mice. Despite the comparable initial response to amphotericin B, liver burdens in nude animals doubled 3 weeks after treatment and then steadily increased (figure 2).
Together, these results reemphasize the critical role ofT cells (and T cell-derived or -regulated cytokines) in preventing spontaneous relapse of previously controlled, quiescent infection and in maintaining the posttreatment response. In euthymic mice with chronic but well-suppressed infection, a multicytokine-dependent mechanism appears to be involved and may be similar to the endogenous response that initiates acquisition of resistance to L. donovani in naive animals. In this latter model, IL-2 induces IFN-y, and IFN-y and TNF-a appear to be linked factors in a more distal antileishmanial effector pathway [9] . Thus, the results in figure 1 suggest that the maintenance of day for a total of three injections [11] . Parasite burdens were measured 2 days, 3 weeks, and 12 weeks after treatment. Euthymic naive BALB/c mice were treated identically. 
Results
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Relapse of chronic quiescent infection in euthymic mice. Following an initial 4-week period during which visceral L. donovani freely replicates, naive euthymic BALB/c mice acquire resistance and proceed to reduce liver and spleen parasite burdens [8] . Thereafter, these mice remain persistently infected at low levels for an indefinite period [8] . These animals resist rechallenge, and their spleen cells respond to specific antigen with IL-2 and IFN-y secretion and transfer resistance to naive mice [8] . As judged by the effects of MAb treatment (figure 1), maintaining intracellular L. donovani in a quiescent state and prevention of reactivation of visceral infection required CD4 cells and appeared to involve a multicytokine-dependent endogenous mechanism. CD8 cells may also playa role, since although the effect induced by anti-CD8 treatment was not significant (P > .05), liver burdens were nevertheless increased 2-fold in CD8 cell-depleted mice. The results shown in figure 1 also suggest that IL-2, IFN-y, and TNF-a each participated in this mechanism. After 8 weeks of anti-cytokine antibody administration, liver parasite burdens were increased 5.0-, 8.3-, and 6.5-fold, respectively, over burdens in mice injected with control preparations.
Posttreatment relapse in nude mice. Nude BALB/c mice, which fail to control L. donovani visceral replication [6, [9] [10] [11] , were selected as a model with which to examine relapse Figure 1 . Reactivation of visceral leishmaniasis in chronically infected euthymic BALB/c mice treated for 8 weeks with T cell-depleting or anti-cytokine antibodies. A, Mice before treatment (day 0). B-I, Mice 8 weeks later (day 56) after no therapy (B); therapy on days 1-3 and twice-weekly thereafter with anti-CD4 (C), anti-CD8 (D), or normal rat IgG (E); or therapy starting on day 1 with twice-weekly injections of anti-interleukin-2 (F), anti-interferon-y (G), anti-tumor necrosis factor-a (H), or normal rabbit serum (I) . Results are mean ± SE for 8 to 9 mice/group (2 experiments). * P < .05 compared with appropriate rat IgG-injected or rabbit serum-injected controls. LDU, Leishman-Donovan units.
immunity (prevention of relapse) in chronic L. donovani infection likely involves the same sequential type of cytokine-mediated mechanism as well. It is possible that IL-12 [10] may also participate as a more proximal endogenous component of this same mechanism.
Since new treatment strategies are needed to address the issue of relapse in T cell-deficient patients with visceral leishmaniasis, both of the models described here may prove useful in testing interventions directed at suppressing reemergence of infection: For example, and consistent with our results in amphotericin B-treated mice, HIV-infected patients with kalaazar also show good initial responses to treatment with lipid formulations of amphotericin B but mostly relapse once therapy is discontinued [14] . Whether this outcome can be successfully altered (e.g., by the addition of long-term cytokine treatment) is not known. IFN-y would seem appropriate to test experimentally, as judged by the capacity of anti-IFN-y treatment to provoke relapse (figure 1) and in view of its already recognized efficacy in both experimental and human kala-azar [15] . CD4 cell-depleted, chronically infected euthymic mice also represent another experimental setting in which it would be logical to test the capacity of exogenous IFN-y or inducers of endogenous IFN-y (IL-2 and IL-12 [9, 10] ) to prevent relapse.
